SCHEMBL27134038

SCHEMBL27134038

CC12CCC(CC1)C(OC(=O)c1ccccc1)C2OC(=O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.47
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ NLRP3 Q96P20 1/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ CHRNA7 P36544 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ HTR3E A5X5Y0 1/20 0.43
▸ HTR3B O95264 1/20 0.43
▸ HTR3A P46098 1/20 0.43
▸ HTR3D Q70Z44 1/20 0.43
▸ HTR3C Q8WXA8 1/20 0.43
▸ TSHR P16473 1/20 0.42
▸ ABCB1 P08183 6/20 0.42
▸ APOBEC3A P31941 1/20 0.42
▸ APOBEC3G Q9HC16 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27134058 0.83 GAA (0.55) GAAMEN1KMT2ATDP1CYP3A4
SCHEMBL27134128 0.83 CHRNA7 (0.41) GAAMEN1KMT2ATDP1CHRNA7
SCHEMBL27134039 0.82 CHRNA7 (0.43) GAAMEN1KMT2ATDP1CHRNA7
SCHEMBL27134041 0.82 CHRNA7 (0.40) GAAMEN1KMT2ATDP1CHRNA7
SCHEMBL27134087 0.82 CHRNA7 (0.40) GAAMEN1KMT2ANLRP3TDP1
SCHEMBL27134091 0.80 CHRNA7 (0.39) GAAMEN1KMT2ATDP1CHRNA7
SCHEMBL27134258 0.79 GAA (0.51) GAAMEN1KMT2ATDP1CYP3A4
SCHEMBL27134271 0.79 GAA (0.51) GAAMEN1KMT2ATDP1CYP3A4
SCHEMBL27138259 0.78 CHRNA7 (0.53) GAAMEN1KMT2ACHRNA7LMNA
SCHEMBL26705642 0.78 CHRNA7 (0.53) GAAMEN1KMT2ACHRNA7LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067764-A1 SOLID TITANIUM CATALYST COMPONENT, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMERIZATION METHOD, AND PROPYLENE POLYMER MITSUI CHEMICALS, INC. (JP) 2024-02-29 — — US disclosed
US-20240067764-A1 SOLID TITANIUM CATALYST COMPONENT, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMERIZATION METHOD, AND PROPYLENE POLYMER MITSUI CHEMICALS, INC. (JP) 2024-02-29 — — US disclosed
US-20240067597-A1 ESTER COMPOUND MITSUI CHEMICALS, INC. (JP) 2024-02-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067597-A1 ESTER COMPOUND PPT1, GPER1, TCP1 GAA 2487/4885MEN1 2318/4885KMT2A 2843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback